Fibrocell Science Inc (FCSC) 2003年年度报告「NASDAQ」.pdf

《Fibrocell Science Inc (FCSC) 2003年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Fibrocell Science Inc (FCSC) 2003年年度报告「NASDAQ」.pdf（61页珍藏版）》请在三个皮匠报告上搜索。

1、Use these links to rapidly review the documentTABLE OF CONTENTS Isolagen,Inc.(A Development Stage Company)Index to Consolidated Financial StatementsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K Annual Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act

2、 of 1934For the fiscal year ended December 31,2003ORoo Transition Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934Isolagen,Inc.(Exact name of registrant as specified in its Charter.)Delaware 0-12666 87-0458888(State or other jurisdictionof incorporation)(Commission File N

3、umber)(I.R.S.EmployerIdentification No.)2500 Wilcrest,5th FloorHouston,Texas 77042(Address of principal executive offices,including zip code)(713)780-4754(Issuers telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of Each Class Name of Each Exchange

4、on which RegisteredCommon Stock,$.001 par value American Stock Exchange Indicate by check mark whether the registrant:(1)filed all reports required to be filed by Section 13 or 15(d)of the Exchange Act during thepreceding 12 months(or for any shorter period that the registrant was required to file s

5、uch reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes o No Indicate by check mark if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-K contained in this form,and nodisclosure will be contained,to the best of registrants knowledge,

6、in definitive proxy or information statements incorporated by reference in Part IIIof this Form 10-K or any amendment to this Form 10-K.Indicate by check mark whether the registrant is an accelerated filer(as defined in the Exchange Act Rule 12b-2)oYes No As of March 24,2004,the aggregate market val